Productivity loss as a major component of disease-related costs in patients with hypercholesterolemia in Germany

Clinical Research in Cardiology

Volumn 97, Issue 3, 2008, Pages 152-159

  Müller Nordhorn, Jacqueline ^a   Englert, Heike ^b   Wegscheider, Karl ^c   Berger, Hendrike ^d   Sonntag, Frank ^e   Völler, Heinz ^f   Meyer Sabellek, Wolfgang ^g   Reinhold, Thomas ^a   Windler, Eberhard ^c   Katus, Hugo A ^h   Willich, Stefan N ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b MÜNSTER UNIVERSITY OF APPLIED SCIENCES   (Germany)

^c UNIVERSITY OF HAMBURG   (Germany)

^d UNIVERSITY OF APPLIED SCIENCES OSNABRÜCK   (Germany)

^e Cardiology Practice   (Germany)

^f Rehabilitation Center for Cardiovascular Diseases   (Germany)

^g ASTRAZENECA R AND D   (Sweden)

^h UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Disease related costs; Hypercholesterolemia

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; AGED; ANAMNESIS; ARTICLE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DIABETES MELLITUS; EMPLOYMENT STATUS; FEMALE; GERMANY; HEALTH CARE COST; HEALTH ECONOMICS; HEALTH PROGRAM; HEART INFARCTION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; LINEAR REGRESSION ANALYSIS; MALE; MULTIVARIATE ANALYSIS; OUTPATIENT CARE; PATIENT COMPLIANCE; PHYSICIAN; PREDICTOR VARIABLE; PRIMARY MEDICAL CARE; PRODUCTIVITY; RANDOMIZED CONTROLLED TRIAL; RETIREMENT; RISK ASSESSMENT; STROKE; WORKING TIME;

CARDIOLOGY SERVICE, HOSPITAL; CARDIOVASCULAR DISEASES; COSTS AND COST ANALYSIS; EFFICIENCY; FEMALE; GERMANY; HUMANS; HYPERCHOLESTEROLEMIA; LENGTH OF STAY; MALE; MIDDLE AGED; PRACTICE GUIDELINES AS TOPIC; QUESTIONNAIRES; RETIREMENT; RETROSPECTIVE STUDIES; RISK FACTORS; SOCIOECONOMIC FACTORS;

EID: 44049104371     PISSN: 18610684     EISSN: 18610692     Source Type: Journal    
DOI: 10.1007/s00392-007-0602-0     Document Type: Article

References (36)

1. Anderson KM, Wilson PW, Odell PM, Kannel WB (1991) An updated coronary risk profile. A statement for health professionals. Circulation 83:356-362
2. Baigent C, Keech A, Kearney PM et al. (2005) Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366:1267-1278
3. Bundesministerium für Gesundheit (2002) Statistisches Taschenbuch Gesundheit 2002. Bundesministerium für Gesundheit, Bonn
4. Cleemput I, Kesteloot K, DeGeest S (2002) A review of the literature on the economics of noncompliance. Room for methodological improvement. Health Policy 59:65-94
5. Drummond M (2001) Introducing economic and quality of life measurements into clinical studies. Ann Med 33:344-349
6. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) (2001). JAMA 285:2486-2497
7. Franco OH, Peeters A, Looman CW, Bonneux L (2005) Cost effectiveness of statins in coronary heart disease. J Epidemiol Community Health 59:927-933
8. Gesundheitsberichterstattung des Bundes (2006) Gesundheit in Deutschland. Robert Koch-Institut, Berlin
9. Grover SA, Ho V, Lavoie F et al. (2003) The importance of indirect costs in primary cardiovascular disease prevention: can we save lives and money with statins? Arch Intern Med 163:333-339
10. Hanoverian Consensus-Group (1999) German recommendations for health economic evaluations-revised version of the Hanover Consensus. Gesundh Ökon Qual Manag 4:A62-A65
11. van Hout BA, Simoons ML (2001) Cost-effectiveness of HMG coenzyme reductase inhibitors; whom to treat? Eur Heart 22:751-761
12. Johannesson M, Jonsson B, Kjekshus J et al. (1997) Cost effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary heart disease. Scandinavian Simvastatin Survival Study Group. N Engl J Med 336:332-336
13. Klever-Deichert G, Hinzpeter B, Wendland G, Lauterbach K (2000) Cost-benefit analysis of an evidence-based secondary prevention of coronary heart diseases by statins. An analysis for Germany from a social security perspective. Med Klin (Munich) 95:305-313
14. Luley C (2006) Lipometabolic disorder-cholesterol and triglycerides. Clin Res Cardiol 95(suppl):VI17-VI22
15. MediMedia GmbH (2002) Gelbe Liste Pharmindex ( http://www.gelbe-liste.de ). MediMedia GmbH, Neu-Isenburg
16. Mihaylova B, Briggs A, Armitage J et al. (2005) Cost-effectiveness of simvastatin in people at different levels of vascular disease risk: economic analysis of a randomised trial in 20,536 individuals. Lancet 365:1779-1785
17. Miller PS, Smith DG, Jones P (2005) Cost effectiveness of rosuvastatin in treating patients to low-density lipoprotein cholesterol goals compared with atorvastatin, pravastatin, and simvastatin (a US Analysis of the STELLAR Trial). Am J Cardiol 95:1314-1319
18. Müller-Nordhorn J, Brüggenjürgen B, Böhmig M et al. (2005) Direct and indirect costs in a prospective cohort of patients with pancreatic cancer. Aliment Pharmacol Ther 22:405-415
19. Müller-Nordhorn J, Reinhold T, Sonntag F, Wegscheider K, Willich SN (2007) Projected trends in costs of patients with hypercholesterolemia in Germany. E-J Cardiol Practice 6
20. Murray CJ, Lauer JA, Hutubessy RC et al. (2003) Effectiveness and costs of interventions to lower systolic blood pressure and cholesterol: a global and regional analysis on reduction of cardiovascular-disease risk. Lancet 361:717-725
21. Neymark N, Adriaenssen I (1999) The costs of managing patients with advanced colorectal cancer in 10 different European centres. Eur J Cancer 35:1789-1795
22. Prevention of coronary heart disease in clinical practice (1998) Recommendations of the Second Joint Task Force of European and other Societies on coronary prevention. Eur Heart J 19:1434-1503
23. Prosser LA, Stinnett AA, Goldman PA et al. (2000) Cost-effectiveness of cholesterol-lowering therapies according to selected patient characteristics. Ann Intern Med 132:769-779
24. Rossnagel K, Nolte CH, Müller-Nordhorn J et al. (2005) Medical resource use and costs of health care after acute stroke in Germany. Eur J Neurol 12:862-868
25. Ruof J, Huelsemann JL, Mittendorf T et al. (2004) Patient-reported health care utilization in rheumatoid arthritis: what level of detail is required? Arthritis Rheum 51:774-781
26. Rychlik R (1999) Gesundheitsökonomie - Grundlagen und Praxis. Enke, Stuttgart, pp 15-172
27. Schwabe U, Pfaff D (2002) Arzneiverordnungsreport 2002. Springer-Verlag, Berlin
28. Statistisches Bundesamt (2003) Die Bevölkerung Deutschlands bis 2050. 10. koordinierte Bevölkerungsvorausberechnung. Statistisches Bundesamt, Bonn
29. Strandberg TE, Lehto S, Pyorala K et al. (1997) Cholesterol lowering after participation in the Scandinavian Simvastatin Survival Study (4S) in Finland. Eur Heart J 18:1725-1727
30. Verband deutscher Rentenversicher ungsträger (VDR) (2003) Durchschnittliche Bruttojahresarbeitsentgelte (http://www.vdr.de/internet/vdr/ statzr.nsf/). Verband deutscher Rentenversicherungsträger, Frankfurt am Main
31. Willich SN, Müller-Nordhorn J, Sonntag F et al. (2004) Economic evaluation of a compliance-enhancing intervention in patients with hypercholesterolemia: design and baseline results of the Open Label Primary Care Study: rosuvastatin based compliance initiatives to achievements of LDL goals (ORBITAL) study. Am Heart J 148:1060-1067
32. Willich SN, Reinhold T, Lenz C, Brüggenjürgen B (2005) Herzinsuffizienz nach Myokardinfarkt in Deutschland - Ökonomische Bedeutung und Einschränkung der Lebensqualität. Pharmacoecon - German Res Art 3:25-39
33. Willich SN, Nocon M, Kulig M et al. (2006) Cost-of-disease analysis in patients with gastro-oesophageal reflux disease and Barrett's mucosa. Aliment Pharmacol Ther 23:371-376
34. World Health Organization (2003) The World Health Report 2002. Reducing risks, promoting healthy life. World Health Organization, Geneva
35. Zentralinstitut für die kassenärztliche Versorgung in der BRD (2002) Die 50 häufigsten Diagnosen von Patienten, Kontakthäufigkeit und angeforderter Leistungsbedarf in Punkten. Zentralinstitut für kassenärztliche Versorgung, Köln
36. Zhou XH, Melfi CA, Hui SL (1997) Methods for comparison of cost data. Ann Intern Med 127:752-756